Evidence map›Paper›PMID 39122918›Full record

ArticlePsychopharmacology2024

Effects of chronic naltrexone treatment on relapse-related behavior and neural responses to fentanyl in awake nonhuman primates.

Sarah L Withey, Harshawardhan U Deshpande, Lei Cao, Jack Bergman, Stephen J Kohut

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah L WitheyBehavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.
Harshawardhan U DeshpandeBehavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.
Lei CaoBehavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.
Jack BergmanBehavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA.
Stephen J KohutBehavioral Biology Program, McLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA, 02478, USA. skohut@mclean.harvard.edu.ORCID http://orcid.org/0000-0002-6906-8818

Funding

Delineating the role of serotonin 5-HT2 receptors in opioid use disorders:Development of novel 5-HT2 modulators with translational studies in rodents andprimatesR01DA047130 · NIDA · NORTHEASTERN UNIVERSITY · PI BOOTH, RAYMOND G., KOHUT, STEPHEN JOHN · 2018 to 2022
$3.2M
Translational models of brain activation patterns during nicotine self-administration and reinstatementK01DA039306 · NIDA · MCLEAN HOSPITAL · PI KOHUT, STEPHEN JOHN · 2015 to 2019
$867k
Alkermes Pathways Research Awards®NIDA NIH HHS K01 DA039306NIDA NIH HHS R01 DA047130Office of National Drug Control Policy S10RR019356
6 · The paper itself

Abstract

Naltrexone, an opioid antagonist that blocks the reinforcing properties of opioid agonists, is often prescribed to preclude relapse to opioid use disorder (OUD) following detoxification. However, few laboratory studies have directly investigated the ability of naltrexone to alter relapse-inducing effects of opioid agonists, including their priming strength in reinstatement studies and their impact in brain regions known to be involved in drug-induced reinforcement in MRI studies. Here we directly address this issue by investigating the effects of continuous exposure to naltrexone on 1) fentanyl-induced reinstatement of drug-seeking behavior, 2) fentanyl-induced patterns of blood oxygenation level dependent (BOLD) activation in the nucleus accumbens (NAcc), and 3) fentanyl-induced changes in NAcc functional connectivity (FC) in awake non-human primates that are engaged in ongoing opioid self-administration studies. We found that naltrexone antagonizes the priming strength of fentanyl as shown by a rightward shift in its reinstatement dose-effect curve and that naltrexone surmountably antagonizes the BOLD response induced by fentanyl. However, while naltrexone also countered fentanyl's effects on NAcc FC, the effects were not surmounted by a higher dose of fentanyl. Together, these data suggest that, in contrast to naltrexone's modulation of fentanyl's effects on behavior and BOLD responses, their interactive effects on FC between multiple brain regions do not reflect their receptor-mediated activity. Additionally, we demonstrated opposing effects in the absence and presence of naltrexone on NAcc FC at baseline (i.e., in the absence of any fentanyl prime) suggesting that naltrexone alters FC at baseline, even though naltrexone appears behaviorally silent in the absence of an agonist prime. Together these data provide additional insight into ways in which naltrexone interacts with opioid agonists, both behaviorally and in the brain. Further understanding the effects of opioid agonists on patterns of FC could help elucidate our understanding of the neural processes that contribute to the initiation of and relapse to opioid-seeking behavior in OUD.

Indexed as

Drug-Seeking BehaviorFentanylNaltrexoneNarcotic AntagonistsNucleus AccumbensRecurrenceSelf AdministrationAnalgesics, OpioidAnimalsDose-Response Relationship, DrugMacaca mulattaMagnetic Resonance ImagingMaleOpioid-Related DisordersAnalgesics, OpioidFentanylNaltrexoneNarcotic AntagonistsChronic naltrexoneFentanylNeuroimagingNonhuman primatesOpioidRelapse (reinstatement)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.